Log in or Sign up for Free to view tailored content for your specialty!
Endocrinology News
Tirzepatide lowers body weight, improves glycemic control for adults with type 1 diabetes
Adults with type 1 diabetes and overweight or obesity prescribed tirzepatide off-label had a reduction in body weight and improvements in HbA1c and continuous glucose monitoring metrics, according to data from a real-world study.
Type of menopausal hormone therapy may influence cancer risk
CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.
Log in or Sign up for Free to view tailored content for your specialty!
Men at higher risk for diabetes-related complications than women
Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.
Bariatric surgery could ‘enhance’ spontaneous fertility for women with PCOS, obesity
Women with polycystic ovary syndrome, obesity and irregular menses were more than twice as likely to experience spontaneous ovulation during the year after undergoing bariatric surgery compared with medical therapy, researchers reported.
Most transgender teens reach adult height close to their sex assigned at birth after HT
Most transgender adolescents receiving a gonadotropin-releasing hormone agonist combined with gender-confirming hormone therapy grow to an adult height close to the reference height for their sex assigned at birth, according to study data.
GLP-1 dispensing among adolescents, young adults rose from 2020 to 2023
Dispensing of GLP-1 receptor agonists increased nearly 600% among adolescents and young adults in the United States from 2020 to 2023 and was particularly significant among girls and young women, a new study showed.
GLP-1s not tied to higher risk for surgical complications for adults with diabetes
Adults with diabetes who used a GLP-1 receptor agonist and underwent surgery requiring general anesthesia had similar odds for postsurgical complications as those receiving other oral diabetes medications, according to study data.
How doctors learn has changed dramatically
Any doctor seeing patients has had to field questions unrelated to their specialty.
Adults with obesity, preexisting CVD maintain weight loss with semaglutide at 4 years
Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.
Umbrella review captures impact of plant-based diets on cancer, cardiometabolic diseases
An umbrella review of 2 decades of research showed that vegan and vegetarian diets were associated with a greater lipid profile and reduced risk for cancer and death.
-
Headline News
Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access
November 11, 20246 min read -
Headline News
Daily oral semaglutide confers weight loss vs. placebo; similar vs. weekly injectables
November 11, 20243 min read -
Headline News
Culture shift needed to reframe cybersecurity as a patient safety issue
November 11, 202410 min read
-
Headline News
Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access
November 11, 20246 min read -
Headline News
Daily oral semaglutide confers weight loss vs. placebo; similar vs. weekly injectables
November 11, 20243 min read -
Headline News
Culture shift needed to reframe cybersecurity as a patient safety issue
November 11, 202410 min read